Call Options

7 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$460.0 - $505.78 $1.33 Million - $1.47 Million
2,900 Added 30.21%
12,500 $5.81 Million
Q2 2024

Aug 14, 2024

BUY
$392.81 - $485.53 $667,777 - $825,401
1,700 Added 21.52%
9,600 $4.5 Million
Q1 2024

May 15, 2024

SELL
$407.69 - $446.08 $693,073 - $758,336
-1,700 Reduced 17.71%
7,900 $3.3 Million
Q4 2023

Feb 14, 2024

BUY
$343.0 - $410.68 $2.81 Million - $3.37 Million
8,200 Added 585.71%
9,600 $3.91 Million
Q2 2023

Aug 14, 2023

BUY
$314.42 - $351.91 $220,094 - $246,337
700 Added 100.0%
1,400 $492,000
Q1 2023

May 15, 2023

BUY
$283.23 - $323.1 $198,261 - $226,170
700 New
700 $220,000
Q2 2022

Aug 15, 2022

BUY
$234.96 - $292.55 $1.34 Million - $1.67 Million
5,700 New
5,700 $1.61 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Squarepoint Ops LLC Portfolio

Follow Squarepoint Ops LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Squarepoint Ops LLC, based on Form 13F filings with the SEC.

News

Stay updated on Squarepoint Ops LLC with notifications on news.